Olmesartanmedoxomil/Amlodipine Stada (Amlodipine, Olmesartan)

Olmesartan, the active ingredient in Olmesartanmedoxomil/Amlodipine Stada, is an angiotensin II receptor blocker presented as a fixed‑dose combination tablet for oral use. It treats hypertension, often in combination with a calcium‑channel blocker, and is indicated for adults. GNH USA supplies Olmesartanmedoxomil/Amlodipine Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartanmedoxomil/Amlodipine Stada is used in cardiovascular therapy, targeting blood‑pressure regulation pathways. - Hypertension: provides additive blood‑pressure reduction by combining an ARB with a calcium‑channel blocker. - Isolated systolic hypertension in the elderly: improves systolic control where vascular stiffness predominates. - Hypertension with concomitant edema risk: mitigates calcium‑channel blocker‑induced peripheral edema through vasodilatory synergy.

Adverse reactions may occur with any antihypertensive regimen and should be monitored during therapy.

Common Side Effects: - Dizziness or light‑headedness - Peripheral edema, especially with amlodipine component - Headache - Flushing - Fatigue - Nasal congestion

Serious or Rare Side Effects: - Angio‑edema involving face, lips or airway - Severe hypotension or syncope - Acute kidney injury or rising serum creatinine - Hyperkalemia - Hepatic enzyme elevation - Myocardial infarction in patients with unstable coronary disease

When prescribing this fixed‑dose combination, clinicians should consider several safety aspects. - Monitor blood pressure: ensure adequate control without excessive lowering. - Assess renal function: adjust use in patients with impaired kidney function. - Check electrolytes: watch for potassium abnormalities. - Evaluate for heart failure: use cautiously in decompensated states. - Review concomitant medications: avoid additive hypotensive agents. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Olmesartanmedoxomil/Amlodipine Stada can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): increased risk of hyperkalaemia and renal impairment. - Potassium‑sparing diuretics or supplements: may precipitate hyperkalaemia. - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): raise amlodipine levels, risking hypotension.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can blunt antihypertensive effect and affect renal function. - Diuretics (especially thiazides): may enhance hypotensive response. - Simvastatin or other statins metabolised by CYP3A4: increased risk of myopathy. - Lithium: may increase serum lithium concentrations. - Alcohol: additive central nervous system depression and blood‑pressure lowering.